SCHEMBL1603828

SCHEMBL1603828

COc1ccc(C(=O)C=Cc2ccc(O)cc2O)cc1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 3/20 0.75
GABRA3 P34903 1/20 0.70
GABRA2 P47869 1/20 0.70
GABRB2 P47870 1/20 0.70
TYR P14679 1/20 0.67
CTSL P07711 3/20 0.66
CTSB P07858 3/20 0.66
TNFRSF1A P19438 1/20 0.66
TDP1 Q9NUW8 1/20 0.66
MAPT P10636 2/20 0.65
P4HB P07237 1/20 0.65
CALM1 P0DP23 1/20 0.65
RAB9A P51151 1/20 0.65
MEN1 O00255 1/20 0.65
ALDH1A1 P00352 1/20 0.65
F3 P13726 1/20 0.65
XDH P47989 1/20 0.65
KMT2A Q03164 1/20 0.65
CAPN1 P07384 1/20 0.62
DPP4 P27487 2/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1603827 1.00 CHRNA7 (0.75) CHRNA7GABRA3GABRA2GABRB2TYR
SCHEMBL28339980 0.94 GABRA3 (0.78) CHRNA7GABRA3GABRA2GABRB2CTSL
SCHEMBL4139154 0.94 GABRA3 (0.78) CHRNA7GABRA3GABRA2GABRB2CTSL
SCHEMBL10384464 0.89 GABRA3 (0.84) GABRA3GABRA2GABRB2CTSLCTSB
SCHEMBL26113846 0.87 CTSB (0.86) CHRNA7GABRA3GABRA2GABRB2CTSL
SCHEMBL1695380 0.86 CHRNA7 (1.00) CHRNA7TYRCTSLCTSBTDP1
SCHEMBL21446884 0.86 CHRNA7 (1.00) CHRNA7TYRCTSLCTSBTDP1
SCHEMBL1695381 0.86 CHRNA7 (1.00) CHRNA7TYRCTSLCTSBTDP1
SCHEMBL28906370 0.86 CTSL (0.63) CHRNA7GABRA3GABRA2GABRB2CTSL
SCHEMBL7656528 0.86 MAPT (0.76) CHRNA7GABRA3GABRA2GABRB2TNFRSF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8242144-B2 Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases RESVERLOGIX CORP. (CA) 2012-08-14 US disclosed
US-20110082176-A1 Stilbenes and Chalcones for the Prevention and Treatment of Cardiovascular Diseases RESVERLOGIX CORP. 2011-04-07 US disclosed
US-7846915-B2 Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases Resverlogix Corporation (CA) 2010-12-07 US disclosed
US-20060205792-A1 Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases HEPALINK (HONG KONG) LIMITED (HK) 2006-09-14 US disclosed
WO-2006045010-A2 STILBENES AND CHALCONES FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES RESVERLOGIX CORP. (CA) 2006-04-27 WO disclosed
US-4867964-A SUNSCREEN L'OREAL (FR) 1989-09-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060205792-A1 Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases APOB, APOL1, HDLBP CHRNA7 3919/4885GABRA3 4781/4885GABRA2 4804/4885
US-20110082176-A1 Stilbenes and Chalcones for the Prevention and Treatment of Cardiovascular Diseases APOB, APOL1, HDLBP CHRNA7 3919/4885GABRA3 4781/4885GABRA2 4804/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.